Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Sold by Rock Springs Capital Management LP

Rock Springs Capital Management LP cut its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 32.6% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 471,086 shares of the biopharmaceutical company's stock after selling 228,303 shares during the period. Rock Springs Capital Management LP owned about 0.83% of Agios Pharmaceuticals worth $15,480,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also made changes to their positions in the company. Vanguard Group Inc. lifted its stake in Agios Pharmaceuticals by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 5,631,321 shares of the biopharmaceutical company's stock worth $185,045,000 after acquiring an additional 85,339 shares during the period. Geode Capital Management LLC lifted its position in shares of Agios Pharmaceuticals by 0.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,357,531 shares of the biopharmaceutical company's stock worth $60,326,000 after purchasing an additional 6,101 shares during the period. Fisher Asset Management LLC boosted its stake in shares of Agios Pharmaceuticals by 12.3% during the fourth quarter. Fisher Asset Management LLC now owns 960,661 shares of the biopharmaceutical company's stock valued at $31,567,000 after purchasing an additional 105,333 shares in the last quarter. Artisan Partners Limited Partnership increased its holdings in Agios Pharmaceuticals by 27.4% during the fourth quarter. Artisan Partners Limited Partnership now owns 499,134 shares of the biopharmaceutical company's stock valued at $16,402,000 after buying an additional 107,292 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its holdings in Agios Pharmaceuticals by 1.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 472,547 shares of the biopharmaceutical company's stock valued at $15,528,000 after buying an additional 6,927 shares during the period.

Analysts Set New Price Targets

Several analysts have issued reports on the company. StockNews.com cut Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Friday, February 14th. HC Wainwright initiated coverage on Agios Pharmaceuticals in a research report on Monday, February 24th. They set a "buy" rating and a $58.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $56.57.

Insider Activity

In related news, Director Jacqualyn A. Fouse sold 7,497 shares of the firm's stock in a transaction on Thursday, April 10th. The shares were sold at an average price of $25.90, for a total transaction of $194,172.30. Following the completion of the transaction, the director now owns 149,220 shares of the company's stock, valued at $3,864,798. This trade represents a 4.78 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 4.93% of the company's stock.

Agios Pharmaceuticals Stock Up 0.6 %

Shares of AGIO traded up $0.19 during mid-day trading on Friday, hitting $29.45. 358,865 shares of the company traded hands, compared to its average volume of 703,953. The business has a 50 day moving average of $30.30 and a 200 day moving average of $38.25. The company has a market capitalization of $1.69 billion, a PE ratio of 2.60 and a beta of 0.83. Agios Pharmaceuticals, Inc. has a 1-year low of $23.42 and a 1-year high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. As a group, research analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.